Related Experiment Video
Updated: Apr 28, 2026
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
HPV-positive HNSCC and Fc-silent PD-1 blockade: a clinical discrepancy that raises next immunological questions
Kohei Okuyama1,2, Junya Fujimoto3,4,5, Souichi Yanamoto6
1Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA KOkuyama@mdanderson.org.
Abstract:
The recent phase 3 trial of the Fc-silent anti-programmed cell death protein-1 (PD-1) antibody finotonlimab demonstrated promising clinical activity in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). However, an unexpected finding emerged: human papillomavirus (HPV)-positive patients-typically responsive to PD-1 blockade-did not appear to benefit, with a subgroup HR favoring the control arm. This clinical discrepancy raises important mechanistic questions. We hypothesize that the abrogation of Fcγ receptor (FcγR)-mediated functions, while designed to preserve PD-1+ T cells, may inadvertently attenuate innate immune mechanisms that are especially relevant in virally driven tumors. In immune-inflamed HPV-positive HNSCC, antitumor activity may depend not only on T-cell activation but also on FcγR-dependent myeloid and natural killer cell function. These considerations prompt further evaluation of how Fc engineering may interact with tumor immune contexture, particularly in virally associated cancers. We suggest experimental validation and stratified analysis in future studies to clarify these context-specific effects.
Insights
Fc-silent anti-PD-1 therapy showed promise in head and neck cancer, but unexpectedly failed in HPV-positive cases. This suggests Fc receptor interactions may be crucial for anti-tumor immunity in viral cancers.
Area of Science:
- Oncology
- Immunology
- Virology
Background:
- The Fc-silent anti-programmed cell death protein-1 (PD-1) antibody, finotonlimab, showed clinical activity in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
- Human papillomavirus (HPV)-positive HNSCC typically responds well to PD-1 blockade, but this trial observed a lack of benefit in this subgroup.
Purpose of the Study:
- To investigate the mechanistic basis for the unexpected lack of efficacy of Fc-silent PD-1 blockade in HPV-positive HNSCC.
- To explore the hypothesis that Fcγ receptor (FcγR)-mediated innate immune functions are critical for anti-tumor activity in virally driven HNSCC.
Main Methods:
- Analysis of phase 3 trial data for finotonlimab in recurrent/metastatic HNSCC.
- Hypothesizing the role of FcγR-mediated myeloid and natural killer cell functions in HPV-positive HNSCC.
Main Results:
- Finotonlimab demonstrated promising activity in HNSCC overall.
- An unexpected finding was the lack of benefit in HPV-positive HNSCC patients, with a hazard ratio favoring the control arm in a subgroup.
Conclusions:
- The abrogation of FcγR-mediated functions by Fc-silent antibodies may attenuate crucial innate immune responses in virally driven tumors.
- Fc engineering strategies need careful consideration regarding their interaction with tumor immune contexture, especially in HPV-associated cancers.
- Further experimental validation and stratified analysis are recommended to understand these context-specific effects.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
